Ocugen shares surged 17% in premarket trading

Tiger Newspress2022-01-10

Ocugen shares surged 17% in premarket trading.

Ocugen(NASDAQ:OCGN)announced that a booster shot of the COVID-19 vaccine candidate it plans to commercialize in the U.S. generated overa 10-fold increase in antibody levels across a range of coronavirus variants.

Disclosing the Phase 2 data posted by its partner Bharat Biotech for Covaxin, Malvern, Pennsylvania-based biotech said that the studies on its effectiveness against the Omicron variant are currently ongoing, and the results would be reported shortly.

In the analysis of those aged 12 – 64 years who received the additional dose six months after the second dose, the wild-type neutralizing antibodies (PRNT50) GMTs rose in a month from the second dose. The antibody levels were detectable in more than 75% of all subjects even after six months from the second dose.

However, from a baseline at six months from the second dose, GMTs against Alpha, Beta, Delta, and Delta plus variants jumped 10·9, 161·0, 264·7, and 174·2 fold, respectively, a month after the booster.

The data on the booster shot indicated no serious adverse events, including hospitalization ordeath, the company added.The study results are yet to undergo peer review.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Mm101
2022-01-11
Mm101
Like
股惑仔79
2022-01-10
股惑仔79
[What]
- Stephanie712:
  Good
koolgal
2022-01-10
koolgal
Wow a new booster shot by Ocugen that can generate 10 times antibodies against Covid-19 variants! That's awesome if it comes to fruition. 🚀🚀🚀🌙🌙🌙
MP88
2022-01-10
MP88
Yaya
Jayoh
2022-01-10
Jayoh
Hi
btoh
2022-01-10
btoh
K

Leave a comment

100

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1151785294?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-01-10 17:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151785294","market":"us","top_or_hot":-1,"title":"Ocugen shares surged 17% in premarket trading","media":"Tiger Newspress","content":"<html><head></head><body><p>Ocugen shares surged 17% in premarket trading.<img src=\"https://static.tigerbbs.com/281335976be995819caec4cc5015a43b\" tg-width=\"711\" tg-height=\"611\" width=\"100%\" height=\"auto\"/></p><p>Ocugen(NASDAQ:OCGN)announced that a booster shot of the COVID-19 vaccine candidate it plans to commercialize in the U.S. generated overa 10-fold increase in antibody levels across a range of coronavirus variants.</p><p>Disclosing the Phase 2 data posted by its partner Bharat Biotech for Covaxin, Malvern, Pennsylvania-based biotech said that the studies on its effectiveness against the Omicron variant are currently ongoing, and the results would be reported shortly.</p><p>In the analysis of those aged 12 – 64 years who received the additional dose six months after the second dose, the wild-type neutralizing antibodies (PRNT50) GMTs rose in a month from the second dose. The antibody levels were detectable in more than 75% of all subjects even after six months from the second dose.</p><p>However, from a baseline at six months from the second dose, GMTs against Alpha, Beta, Delta, and Delta plus variants jumped 10·9, 161·0, 264·7, and 174·2 fold, respectively, a month after the booster.</p><p>The data on the booster shot indicated no serious adverse events, including hospitalization ordeath, the company added.The study results are yet to undergo peer review.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen shares surged 17% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen shares surged 17% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n2022-01-10 17:04 北京时间&nbsp;&nbsp;&nbsp;<strong>Tiger Newspress</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen shares surged 17% in premarket trading.Ocugen(NASDAQ:OCGN)announced that a booster shot of the COVID-19 vaccine candidate it plans to commercialize in the U.S. generated overa 10-fold increase ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCGN","symbol_name":"Ocugen","start_time":0,"source_url":"","article_id":"1151785294","we_media_id":"1079075236","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151785294","pubTimestamp":1641805482,"sourceInfo":null,"weMediaInfo":{"media_name":"Tiger Newspress","introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"Ocugen shares surged 17% in premarket trading.Ocugen(NASDAQ:OCGN)announced that a booster shot of th","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OCGN":"Ocugen"},"translate_title":"Ocugen股价在盘前交易中飙升17%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCGN":0.9},"content_text":"Ocugen shares surged 17% in premarket trading.Ocugen(NASDAQ:OCGN)announced that a booster shot of the COVID-19 vaccine candidate it plans to commercialize in the U.S. generated overa 10-fold increase in antibody levels across a range of coronavirus variants.Disclosing the Phase 2 data posted by its partner Bharat Biotech for Covaxin, Malvern, Pennsylvania-based biotech said that the studies on its effectiveness against the Omicron variant are currently ongoing, and the results would be reported shortly.In the analysis of those aged 12 – 64 years who received the additional dose six months after the second dose, the wild-type neutralizing antibodies (PRNT50) GMTs rose in a month from the second dose. The antibody levels were detectable in more than 75% of all subjects even after six months from the second dose.However, from a baseline at six months from the second dose, GMTs against Alpha, Beta, Delta, and Delta plus variants jumped 10·9, 161·0, 264·7, and 174·2 fold, respectively, a month after the booster.The data on the booster shot indicated no serious adverse events, including hospitalization ordeath, the company added.The study results are yet to undergo peer review.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9006710855,"gmtCreate":1641850220004,"gmtModify":1676533652854,"author":{"id":"3565081661382277","authorId":"3565081661382277","name":"Mm101","avatar":"https://static.tigerbbs.com/01758aa877d9e5a9767d24de3a4e2ff1","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3565081661382277","authorIdStr":"3565081661382277"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006710855","repostId":1151785294,"repostType":4,"repost":{"id":"1151785294","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1641805482,"share":"https://ttm.financial/m/news/1151785294?lang=&edition=fundamental","pubTime":"2022-01-10 17:04","market":"us","language":"en","title":"Ocugen shares surged 17% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1151785294","media":"Tiger Newspress","summary":"Ocugen shares surged 17% in premarket trading.Ocugen(NASDAQ:OCGN)announced that a booster shot of th","content":"<html><head></head><body><p>Ocugen shares surged 17% in premarket trading.<img src=\"https://static.tigerbbs.com/281335976be995819caec4cc5015a43b\" tg-width=\"711\" tg-height=\"611\" width=\"100%\" height=\"auto\"/></p><p>Ocugen(NASDAQ:OCGN)announced that a booster shot of the COVID-19 vaccine candidate it plans to commercialize in the U.S. generated overa 10-fold increase in antibody levels across a range of coronavirus variants.</p><p>Disclosing the Phase 2 data posted by its partner Bharat Biotech for Covaxin, Malvern, Pennsylvania-based biotech said that the studies on its effectiveness against the Omicron variant are currently ongoing, and the results would be reported shortly.</p><p>In the analysis of those aged 12 – 64 years who received the additional dose six months after the second dose, the wild-type neutralizing antibodies (PRNT50) GMTs rose in a month from the second dose. The antibody levels were detectable in more than 75% of all subjects even after six months from the second dose.</p><p>However, from a baseline at six months from the second dose, GMTs against Alpha, Beta, Delta, and Delta plus variants jumped 10·9, 161·0, 264·7, and 174·2 fold, respectively, a month after the booster.</p><p>The data on the booster shot indicated no serious adverse events, including hospitalization ordeath, the company added.The study results are yet to undergo peer review.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen shares surged 17% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen shares surged 17% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-10 17:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Ocugen shares surged 17% in premarket trading.<img src=\"https://static.tigerbbs.com/281335976be995819caec4cc5015a43b\" tg-width=\"711\" tg-height=\"611\" width=\"100%\" height=\"auto\"/></p><p>Ocugen(NASDAQ:OCGN)announced that a booster shot of the COVID-19 vaccine candidate it plans to commercialize in the U.S. generated overa 10-fold increase in antibody levels across a range of coronavirus variants.</p><p>Disclosing the Phase 2 data posted by its partner Bharat Biotech for Covaxin, Malvern, Pennsylvania-based biotech said that the studies on its effectiveness against the Omicron variant are currently ongoing, and the results would be reported shortly.</p><p>In the analysis of those aged 12 – 64 years who received the additional dose six months after the second dose, the wild-type neutralizing antibodies (PRNT50) GMTs rose in a month from the second dose. The antibody levels were detectable in more than 75% of all subjects even after six months from the second dose.</p><p>However, from a baseline at six months from the second dose, GMTs against Alpha, Beta, Delta, and Delta plus variants jumped 10·9, 161·0, 264·7, and 174·2 fold, respectively, a month after the booster.</p><p>The data on the booster shot indicated no serious adverse events, including hospitalization ordeath, the company added.The study results are yet to undergo peer review.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151785294","content_text":"Ocugen shares surged 17% in premarket trading.Ocugen(NASDAQ:OCGN)announced that a booster shot of the COVID-19 vaccine candidate it plans to commercialize in the U.S. generated overa 10-fold increase in antibody levels across a range of coronavirus variants.Disclosing the Phase 2 data posted by its partner Bharat Biotech for Covaxin, Malvern, Pennsylvania-based biotech said that the studies on its effectiveness against the Omicron variant are currently ongoing, and the results would be reported shortly.In the analysis of those aged 12 – 64 years who received the additional dose six months after the second dose, the wild-type neutralizing antibodies (PRNT50) GMTs rose in a month from the second dose. The antibody levels were detectable in more than 75% of all subjects even after six months from the second dose.However, from a baseline at six months from the second dose, GMTs against Alpha, Beta, Delta, and Delta plus variants jumped 10·9, 161·0, 264·7, and 174·2 fold, respectively, a month after the booster.The data on the booster shot indicated no serious adverse events, including hospitalization ordeath, the company added.The study results are yet to undergo peer review.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":694312654,"gmtCreate":1641816092493,"gmtModify":1676532556955,"author":{"id":"3577415105079753","authorId":"3577415105079753","name":"股惑仔79","avatar":"https://static.tigerbbs.com/2521bf7235578dd93b9e7d10c59d5058","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577415105079753","authorIdStr":"3577415105079753"},"htmlText":"[What]&nbsp;","listText":"[What]&nbsp;","text":"[What]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/694312654","repostId":1151785294,"repostType":4,"repost":{"id":"1151785294","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1641805482,"share":"https://ttm.financial/m/news/1151785294?lang=&edition=fundamental","pubTime":"2022-01-10 17:04","market":"us","language":"en","title":"Ocugen shares surged 17% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1151785294","media":"Tiger Newspress","summary":"Ocugen shares surged 17% in premarket trading.Ocugen(NASDAQ:OCGN)announced that a booster shot of th","content":"<html><head></head><body><p>Ocugen shares surged 17% in premarket trading.<img src=\"https://static.tigerbbs.com/281335976be995819caec4cc5015a43b\" tg-width=\"711\" tg-height=\"611\" width=\"100%\" height=\"auto\"/></p><p>Ocugen(NASDAQ:OCGN)announced that a booster shot of the COVID-19 vaccine candidate it plans to commercialize in the U.S. generated overa 10-fold increase in antibody levels across a range of coronavirus variants.</p><p>Disclosing the Phase 2 data posted by its partner Bharat Biotech for Covaxin, Malvern, Pennsylvania-based biotech said that the studies on its effectiveness against the Omicron variant are currently ongoing, and the results would be reported shortly.</p><p>In the analysis of those aged 12 – 64 years who received the additional dose six months after the second dose, the wild-type neutralizing antibodies (PRNT50) GMTs rose in a month from the second dose. The antibody levels were detectable in more than 75% of all subjects even after six months from the second dose.</p><p>However, from a baseline at six months from the second dose, GMTs against Alpha, Beta, Delta, and Delta plus variants jumped 10·9, 161·0, 264·7, and 174·2 fold, respectively, a month after the booster.</p><p>The data on the booster shot indicated no serious adverse events, including hospitalization ordeath, the company added.The study results are yet to undergo peer review.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen shares surged 17% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen shares surged 17% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-10 17:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Ocugen shares surged 17% in premarket trading.<img src=\"https://static.tigerbbs.com/281335976be995819caec4cc5015a43b\" tg-width=\"711\" tg-height=\"611\" width=\"100%\" height=\"auto\"/></p><p>Ocugen(NASDAQ:OCGN)announced that a booster shot of the COVID-19 vaccine candidate it plans to commercialize in the U.S. generated overa 10-fold increase in antibody levels across a range of coronavirus variants.</p><p>Disclosing the Phase 2 data posted by its partner Bharat Biotech for Covaxin, Malvern, Pennsylvania-based biotech said that the studies on its effectiveness against the Omicron variant are currently ongoing, and the results would be reported shortly.</p><p>In the analysis of those aged 12 – 64 years who received the additional dose six months after the second dose, the wild-type neutralizing antibodies (PRNT50) GMTs rose in a month from the second dose. The antibody levels were detectable in more than 75% of all subjects even after six months from the second dose.</p><p>However, from a baseline at six months from the second dose, GMTs against Alpha, Beta, Delta, and Delta plus variants jumped 10·9, 161·0, 264·7, and 174·2 fold, respectively, a month after the booster.</p><p>The data on the booster shot indicated no serious adverse events, including hospitalization ordeath, the company added.The study results are yet to undergo peer review.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151785294","content_text":"Ocugen shares surged 17% in premarket trading.Ocugen(NASDAQ:OCGN)announced that a booster shot of the COVID-19 vaccine candidate it plans to commercialize in the U.S. generated overa 10-fold increase in antibody levels across a range of coronavirus variants.Disclosing the Phase 2 data posted by its partner Bharat Biotech for Covaxin, Malvern, Pennsylvania-based biotech said that the studies on its effectiveness against the Omicron variant are currently ongoing, and the results would be reported shortly.In the analysis of those aged 12 – 64 years who received the additional dose six months after the second dose, the wild-type neutralizing antibodies (PRNT50) GMTs rose in a month from the second dose. The antibody levels were detectable in more than 75% of all subjects even after six months from the second dose.However, from a baseline at six months from the second dose, GMTs against Alpha, Beta, Delta, and Delta plus variants jumped 10·9, 161·0, 264·7, and 174·2 fold, respectively, a month after the booster.The data on the booster shot indicated no serious adverse events, including hospitalization ordeath, the company added.The study results are yet to undergo peer review.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7167929,"gmtCreate":1641816404239,"gmtModify":1663239452140,"authorId":3582030171524236,"author":{"id":3582030171524236,"idStr":"3582030171524236","authorId":3582030171524236,"name":"Stephanie712","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":694312654,"type":1,"supId":0,"prevId":0,"content":"Good","text":"Good","html":"Good"}],"langContent":"CN"},{"id":9006438601,"gmtCreate":1641813754829,"gmtModify":1676533649997,"author":{"id":"3559581955535845","authorId":"3559581955535845","name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":6,"crmLevelSwitch":1,"idStr":"3559581955535845","authorIdStr":"3559581955535845"},"htmlText":"Wow a new booster shot by Ocugen that can generate 10 times antibodies against Covid-19 variants!&nbsp; That's awesome if it comes to fruition. 🚀🚀🚀🌙🌙🌙","listText":"Wow a new booster shot by Ocugen that can generate 10 times antibodies against Covid-19 variants!&nbsp; That's awesome if it comes to fruition. 🚀🚀🚀🌙🌙🌙","text":"Wow a new booster shot by Ocugen that can generate 10 times antibodies against Covid-19 variants! That's awesome if it comes to fruition. 🚀🚀🚀🌙🌙🌙","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":16,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006438601","repostId":1151785294,"repostType":4,"repost":{"id":"1151785294","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1641805482,"share":"https://ttm.financial/m/news/1151785294?lang=&edition=fundamental","pubTime":"2022-01-10 17:04","market":"us","language":"en","title":"Ocugen shares surged 17% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1151785294","media":"Tiger Newspress","summary":"Ocugen shares surged 17% in premarket trading.Ocugen(NASDAQ:OCGN)announced that a booster shot of th","content":"<html><head></head><body><p>Ocugen shares surged 17% in premarket trading.<img src=\"https://static.tigerbbs.com/281335976be995819caec4cc5015a43b\" tg-width=\"711\" tg-height=\"611\" width=\"100%\" height=\"auto\"/></p><p>Ocugen(NASDAQ:OCGN)announced that a booster shot of the COVID-19 vaccine candidate it plans to commercialize in the U.S. generated overa 10-fold increase in antibody levels across a range of coronavirus variants.</p><p>Disclosing the Phase 2 data posted by its partner Bharat Biotech for Covaxin, Malvern, Pennsylvania-based biotech said that the studies on its effectiveness against the Omicron variant are currently ongoing, and the results would be reported shortly.</p><p>In the analysis of those aged 12 – 64 years who received the additional dose six months after the second dose, the wild-type neutralizing antibodies (PRNT50) GMTs rose in a month from the second dose. The antibody levels were detectable in more than 75% of all subjects even after six months from the second dose.</p><p>However, from a baseline at six months from the second dose, GMTs against Alpha, Beta, Delta, and Delta plus variants jumped 10·9, 161·0, 264·7, and 174·2 fold, respectively, a month after the booster.</p><p>The data on the booster shot indicated no serious adverse events, including hospitalization ordeath, the company added.The study results are yet to undergo peer review.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen shares surged 17% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen shares surged 17% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-10 17:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Ocugen shares surged 17% in premarket trading.<img src=\"https://static.tigerbbs.com/281335976be995819caec4cc5015a43b\" tg-width=\"711\" tg-height=\"611\" width=\"100%\" height=\"auto\"/></p><p>Ocugen(NASDAQ:OCGN)announced that a booster shot of the COVID-19 vaccine candidate it plans to commercialize in the U.S. generated overa 10-fold increase in antibody levels across a range of coronavirus variants.</p><p>Disclosing the Phase 2 data posted by its partner Bharat Biotech for Covaxin, Malvern, Pennsylvania-based biotech said that the studies on its effectiveness against the Omicron variant are currently ongoing, and the results would be reported shortly.</p><p>In the analysis of those aged 12 – 64 years who received the additional dose six months after the second dose, the wild-type neutralizing antibodies (PRNT50) GMTs rose in a month from the second dose. The antibody levels were detectable in more than 75% of all subjects even after six months from the second dose.</p><p>However, from a baseline at six months from the second dose, GMTs against Alpha, Beta, Delta, and Delta plus variants jumped 10·9, 161·0, 264·7, and 174·2 fold, respectively, a month after the booster.</p><p>The data on the booster shot indicated no serious adverse events, including hospitalization ordeath, the company added.The study results are yet to undergo peer review.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151785294","content_text":"Ocugen shares surged 17% in premarket trading.Ocugen(NASDAQ:OCGN)announced that a booster shot of the COVID-19 vaccine candidate it plans to commercialize in the U.S. generated overa 10-fold increase in antibody levels across a range of coronavirus variants.Disclosing the Phase 2 data posted by its partner Bharat Biotech for Covaxin, Malvern, Pennsylvania-based biotech said that the studies on its effectiveness against the Omicron variant are currently ongoing, and the results would be reported shortly.In the analysis of those aged 12 – 64 years who received the additional dose six months after the second dose, the wild-type neutralizing antibodies (PRNT50) GMTs rose in a month from the second dose. The antibody levels were detectable in more than 75% of all subjects even after six months from the second dose.However, from a baseline at six months from the second dose, GMTs against Alpha, Beta, Delta, and Delta plus variants jumped 10·9, 161·0, 264·7, and 174·2 fold, respectively, a month after the booster.The data on the booster shot indicated no serious adverse events, including hospitalization ordeath, the company added.The study results are yet to undergo peer review.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9006405010,"gmtCreate":1641808173361,"gmtModify":1676533649562,"author":{"id":"3582798202671514","authorId":"3582798202671514","name":"MP88","avatar":"https://static.tigerbbs.com/98ab4cdb5a6f628d50eef8b5db5303aa","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582798202671514","authorIdStr":"3582798202671514"},"htmlText":"Yaya","listText":"Yaya","text":"Yaya","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006405010","repostId":1151785294,"repostType":4,"repost":{"id":"1151785294","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1641805482,"share":"https://ttm.financial/m/news/1151785294?lang=&edition=fundamental","pubTime":"2022-01-10 17:04","market":"us","language":"en","title":"Ocugen shares surged 17% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1151785294","media":"Tiger Newspress","summary":"Ocugen shares surged 17% in premarket trading.Ocugen(NASDAQ:OCGN)announced that a booster shot of th","content":"<html><head></head><body><p>Ocugen shares surged 17% in premarket trading.<img src=\"https://static.tigerbbs.com/281335976be995819caec4cc5015a43b\" tg-width=\"711\" tg-height=\"611\" width=\"100%\" height=\"auto\"/></p><p>Ocugen(NASDAQ:OCGN)announced that a booster shot of the COVID-19 vaccine candidate it plans to commercialize in the U.S. generated overa 10-fold increase in antibody levels across a range of coronavirus variants.</p><p>Disclosing the Phase 2 data posted by its partner Bharat Biotech for Covaxin, Malvern, Pennsylvania-based biotech said that the studies on its effectiveness against the Omicron variant are currently ongoing, and the results would be reported shortly.</p><p>In the analysis of those aged 12 – 64 years who received the additional dose six months after the second dose, the wild-type neutralizing antibodies (PRNT50) GMTs rose in a month from the second dose. The antibody levels were detectable in more than 75% of all subjects even after six months from the second dose.</p><p>However, from a baseline at six months from the second dose, GMTs against Alpha, Beta, Delta, and Delta plus variants jumped 10·9, 161·0, 264·7, and 174·2 fold, respectively, a month after the booster.</p><p>The data on the booster shot indicated no serious adverse events, including hospitalization ordeath, the company added.The study results are yet to undergo peer review.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen shares surged 17% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen shares surged 17% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-10 17:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Ocugen shares surged 17% in premarket trading.<img src=\"https://static.tigerbbs.com/281335976be995819caec4cc5015a43b\" tg-width=\"711\" tg-height=\"611\" width=\"100%\" height=\"auto\"/></p><p>Ocugen(NASDAQ:OCGN)announced that a booster shot of the COVID-19 vaccine candidate it plans to commercialize in the U.S. generated overa 10-fold increase in antibody levels across a range of coronavirus variants.</p><p>Disclosing the Phase 2 data posted by its partner Bharat Biotech for Covaxin, Malvern, Pennsylvania-based biotech said that the studies on its effectiveness against the Omicron variant are currently ongoing, and the results would be reported shortly.</p><p>In the analysis of those aged 12 – 64 years who received the additional dose six months after the second dose, the wild-type neutralizing antibodies (PRNT50) GMTs rose in a month from the second dose. The antibody levels were detectable in more than 75% of all subjects even after six months from the second dose.</p><p>However, from a baseline at six months from the second dose, GMTs against Alpha, Beta, Delta, and Delta plus variants jumped 10·9, 161·0, 264·7, and 174·2 fold, respectively, a month after the booster.</p><p>The data on the booster shot indicated no serious adverse events, including hospitalization ordeath, the company added.The study results are yet to undergo peer review.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151785294","content_text":"Ocugen shares surged 17% in premarket trading.Ocugen(NASDAQ:OCGN)announced that a booster shot of the COVID-19 vaccine candidate it plans to commercialize in the U.S. generated overa 10-fold increase in antibody levels across a range of coronavirus variants.Disclosing the Phase 2 data posted by its partner Bharat Biotech for Covaxin, Malvern, Pennsylvania-based biotech said that the studies on its effectiveness against the Omicron variant are currently ongoing, and the results would be reported shortly.In the analysis of those aged 12 – 64 years who received the additional dose six months after the second dose, the wild-type neutralizing antibodies (PRNT50) GMTs rose in a month from the second dose. The antibody levels were detectable in more than 75% of all subjects even after six months from the second dose.However, from a baseline at six months from the second dose, GMTs against Alpha, Beta, Delta, and Delta plus variants jumped 10·9, 161·0, 264·7, and 174·2 fold, respectively, a month after the booster.The data on the booster shot indicated no serious adverse events, including hospitalization ordeath, the company added.The study results are yet to undergo peer review.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9006402170,"gmtCreate":1641807823025,"gmtModify":1676533649553,"author":{"id":"3585096258703639","authorId":"3585096258703639","name":"Jayoh","avatar":"https://static.tigerbbs.com/71560af73fe3c9e5acc4279aa84f7282","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3585096258703639","authorIdStr":"3585096258703639"},"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006402170","repostId":1151785294,"repostType":4,"repost":{"id":"1151785294","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1641805482,"share":"https://ttm.financial/m/news/1151785294?lang=&edition=fundamental","pubTime":"2022-01-10 17:04","market":"us","language":"en","title":"Ocugen shares surged 17% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1151785294","media":"Tiger Newspress","summary":"Ocugen shares surged 17% in premarket trading.Ocugen(NASDAQ:OCGN)announced that a booster shot of th","content":"<html><head></head><body><p>Ocugen shares surged 17% in premarket trading.<img src=\"https://static.tigerbbs.com/281335976be995819caec4cc5015a43b\" tg-width=\"711\" tg-height=\"611\" width=\"100%\" height=\"auto\"/></p><p>Ocugen(NASDAQ:OCGN)announced that a booster shot of the COVID-19 vaccine candidate it plans to commercialize in the U.S. generated overa 10-fold increase in antibody levels across a range of coronavirus variants.</p><p>Disclosing the Phase 2 data posted by its partner Bharat Biotech for Covaxin, Malvern, Pennsylvania-based biotech said that the studies on its effectiveness against the Omicron variant are currently ongoing, and the results would be reported shortly.</p><p>In the analysis of those aged 12 – 64 years who received the additional dose six months after the second dose, the wild-type neutralizing antibodies (PRNT50) GMTs rose in a month from the second dose. The antibody levels were detectable in more than 75% of all subjects even after six months from the second dose.</p><p>However, from a baseline at six months from the second dose, GMTs against Alpha, Beta, Delta, and Delta plus variants jumped 10·9, 161·0, 264·7, and 174·2 fold, respectively, a month after the booster.</p><p>The data on the booster shot indicated no serious adverse events, including hospitalization ordeath, the company added.The study results are yet to undergo peer review.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen shares surged 17% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen shares surged 17% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-10 17:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Ocugen shares surged 17% in premarket trading.<img src=\"https://static.tigerbbs.com/281335976be995819caec4cc5015a43b\" tg-width=\"711\" tg-height=\"611\" width=\"100%\" height=\"auto\"/></p><p>Ocugen(NASDAQ:OCGN)announced that a booster shot of the COVID-19 vaccine candidate it plans to commercialize in the U.S. generated overa 10-fold increase in antibody levels across a range of coronavirus variants.</p><p>Disclosing the Phase 2 data posted by its partner Bharat Biotech for Covaxin, Malvern, Pennsylvania-based biotech said that the studies on its effectiveness against the Omicron variant are currently ongoing, and the results would be reported shortly.</p><p>In the analysis of those aged 12 – 64 years who received the additional dose six months after the second dose, the wild-type neutralizing antibodies (PRNT50) GMTs rose in a month from the second dose. The antibody levels were detectable in more than 75% of all subjects even after six months from the second dose.</p><p>However, from a baseline at six months from the second dose, GMTs against Alpha, Beta, Delta, and Delta plus variants jumped 10·9, 161·0, 264·7, and 174·2 fold, respectively, a month after the booster.</p><p>The data on the booster shot indicated no serious adverse events, including hospitalization ordeath, the company added.The study results are yet to undergo peer review.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151785294","content_text":"Ocugen shares surged 17% in premarket trading.Ocugen(NASDAQ:OCGN)announced that a booster shot of the COVID-19 vaccine candidate it plans to commercialize in the U.S. generated overa 10-fold increase in antibody levels across a range of coronavirus variants.Disclosing the Phase 2 data posted by its partner Bharat Biotech for Covaxin, Malvern, Pennsylvania-based biotech said that the studies on its effectiveness against the Omicron variant are currently ongoing, and the results would be reported shortly.In the analysis of those aged 12 – 64 years who received the additional dose six months after the second dose, the wild-type neutralizing antibodies (PRNT50) GMTs rose in a month from the second dose. The antibody levels were detectable in more than 75% of all subjects even after six months from the second dose.However, from a baseline at six months from the second dose, GMTs against Alpha, Beta, Delta, and Delta plus variants jumped 10·9, 161·0, 264·7, and 174·2 fold, respectively, a month after the booster.The data on the booster shot indicated no serious adverse events, including hospitalization ordeath, the company added.The study results are yet to undergo peer review.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9006408459,"gmtCreate":1641806599598,"gmtModify":1676533649469,"author":{"id":"3573789293829232","authorId":"3573789293829232","name":"btoh","avatar":"https://static.tigerbbs.com/5a7c2d714604fc804a48646ee397f912","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3573789293829232","authorIdStr":"3573789293829232"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006408459","repostId":1151785294,"repostType":4,"repost":{"id":"1151785294","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1641805482,"share":"https://ttm.financial/m/news/1151785294?lang=&edition=fundamental","pubTime":"2022-01-10 17:04","market":"us","language":"en","title":"Ocugen shares surged 17% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1151785294","media":"Tiger Newspress","summary":"Ocugen shares surged 17% in premarket trading.Ocugen(NASDAQ:OCGN)announced that a booster shot of th","content":"<html><head></head><body><p>Ocugen shares surged 17% in premarket trading.<img src=\"https://static.tigerbbs.com/281335976be995819caec4cc5015a43b\" tg-width=\"711\" tg-height=\"611\" width=\"100%\" height=\"auto\"/></p><p>Ocugen(NASDAQ:OCGN)announced that a booster shot of the COVID-19 vaccine candidate it plans to commercialize in the U.S. generated overa 10-fold increase in antibody levels across a range of coronavirus variants.</p><p>Disclosing the Phase 2 data posted by its partner Bharat Biotech for Covaxin, Malvern, Pennsylvania-based biotech said that the studies on its effectiveness against the Omicron variant are currently ongoing, and the results would be reported shortly.</p><p>In the analysis of those aged 12 – 64 years who received the additional dose six months after the second dose, the wild-type neutralizing antibodies (PRNT50) GMTs rose in a month from the second dose. The antibody levels were detectable in more than 75% of all subjects even after six months from the second dose.</p><p>However, from a baseline at six months from the second dose, GMTs against Alpha, Beta, Delta, and Delta plus variants jumped 10·9, 161·0, 264·7, and 174·2 fold, respectively, a month after the booster.</p><p>The data on the booster shot indicated no serious adverse events, including hospitalization ordeath, the company added.The study results are yet to undergo peer review.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen shares surged 17% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen shares surged 17% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-10 17:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Ocugen shares surged 17% in premarket trading.<img src=\"https://static.tigerbbs.com/281335976be995819caec4cc5015a43b\" tg-width=\"711\" tg-height=\"611\" width=\"100%\" height=\"auto\"/></p><p>Ocugen(NASDAQ:OCGN)announced that a booster shot of the COVID-19 vaccine candidate it plans to commercialize in the U.S. generated overa 10-fold increase in antibody levels across a range of coronavirus variants.</p><p>Disclosing the Phase 2 data posted by its partner Bharat Biotech for Covaxin, Malvern, Pennsylvania-based biotech said that the studies on its effectiveness against the Omicron variant are currently ongoing, and the results would be reported shortly.</p><p>In the analysis of those aged 12 – 64 years who received the additional dose six months after the second dose, the wild-type neutralizing antibodies (PRNT50) GMTs rose in a month from the second dose. The antibody levels were detectable in more than 75% of all subjects even after six months from the second dose.</p><p>However, from a baseline at six months from the second dose, GMTs against Alpha, Beta, Delta, and Delta plus variants jumped 10·9, 161·0, 264·7, and 174·2 fold, respectively, a month after the booster.</p><p>The data on the booster shot indicated no serious adverse events, including hospitalization ordeath, the company added.The study results are yet to undergo peer review.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151785294","content_text":"Ocugen shares surged 17% in premarket trading.Ocugen(NASDAQ:OCGN)announced that a booster shot of the COVID-19 vaccine candidate it plans to commercialize in the U.S. generated overa 10-fold increase in antibody levels across a range of coronavirus variants.Disclosing the Phase 2 data posted by its partner Bharat Biotech for Covaxin, Malvern, Pennsylvania-based biotech said that the studies on its effectiveness against the Omicron variant are currently ongoing, and the results would be reported shortly.In the analysis of those aged 12 – 64 years who received the additional dose six months after the second dose, the wild-type neutralizing antibodies (PRNT50) GMTs rose in a month from the second dose. The antibody levels were detectable in more than 75% of all subjects even after six months from the second dose.However, from a baseline at six months from the second dose, GMTs against Alpha, Beta, Delta, and Delta plus variants jumped 10·9, 161·0, 264·7, and 174·2 fold, respectively, a month after the booster.The data on the booster shot indicated no serious adverse events, including hospitalization ordeath, the company added.The study results are yet to undergo peer review.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":100,"commentSize":11,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1151785294"}